BioWorld

Aug. 12, 2010

View Archived Issues

Dicerna Raises $25M Series B to Fund RNAi Cancer Program

Read More

Aegerion Re-Files $86M IPO to Back Cholesterol Drug

Read More

Amgen's Vectibix Disappoints in Head/Neck Cancer Trial

Read More

Other News To Note

Read More

Stock Movers

Read More

Clinic Roundup

Read More

Alectos to Study Alzheimer's Target in Merck $289M Deal

Alectos Therapeutics Inc. will receive up to $289 million in an up-front fee and milestone payments under a collaboration with Merck & Co. to study a potential non-amyloid approach to treat Alzheimer's disease. (BioWorld Today) Read More

FDA Panel Gives Thumbs Up for Valeant Epilepsy Drug

Read More